Navigation Links
Melanoma lurks in larger skin lesions, NYU researchers find
Date:4/22/2008

Skin lesions that are about the size of a pencil eraser are more likely to be melanomas, a deadly form of skin cancer, than smaller moles, according to a new study led by NYU Langone Medical Center researchers.

In a new study published in the April issue of Archives of Dermatology, the NYU researchers confirm that an important warning sign of melanoma moles that are larger than 6 millimeters, the size of a pencil eraser is still valid. In recent years, some researchers have argued that strict adherence to this guideline may make clinicians miss smaller melanomas.

Diameter is a reasonable guideline to pay attention to and we did not see any reason to change it, says David Polsky, M.D., Ph.D., assistant professor of dermatology and associate director of the Pigmented Lesions Section in the Roland O. Perelman Department of Dermatology at NYU School of Medicine, who led the study.

Lesions that are smaller than 6 millimeters are unlikely to be melanoma. New and changing lesions are the most concerning, and lesions that are multiple colors are especially suspicious, says Dr. Polsky.

More than 20 years ago, NYU dermatologists developed a widely used rule, the ABCD acronym, for recognizing growths on the skin that could be early melanomas. They recently added the letter E to the list. The warning signs are: A for asymmetrical lesions; B, lesions with irregular borders; C, lesions with multiple colors; D, for lesions larger than 6 millimeters; and E for evolving lesions that change in size, color, shape or symptoms such as itching over time.

The incidence of melanoma continues to rise. The American Cancer Society estimates that in 2008 there will be 62,480 new cases of melanoma in the United States. About 8,420 people will die of this disease this year. Excessive exposure to sunlight, a fair complexion, a family history of melanoma, and numerous moles, among other factors, place people at higher risk for the disease.

In the new study, Dr. Polsky and his colleagues used a computerized imaging system to measure the lesions in a large database of melanoma cases. They evaluated the lesions of 1,323 patients undergoing biopsies of 1,657 suspicious pigmented lesions. Based on their analysis, 804 or 48.5 percent of the lesions were larger than 6 millimeters in diameter and 138 or 8.3 percent were diagnosed as melanoma. Invasive melanoma, which has penetrated deeper into the skin and is most life threatening, was diagnosed in only 13 or 1.5 percent of 853 lesions that were 6 millimeters or smaller in diameter. By contrast, the invasive type was diagnosed in 41 or 5.1 percent of 804 lesions larger than 6 millimeters.

In situ melanomas, which are less dangerous because they remain in the skins outer layers, were diagnosed in 22 or 2.6 percent of 853 lesions 6 millimeters or smaller in diameter and in 62 or 7.7 percent of 804 lesions larger than 6 millimeters.


'/>"/>

Contact: Jennifer Berman
Jennifer.Berman@nyumc.org
212-404-3555
New York University Medical Center and School of Medicine
Source:Eurekalert

Related medicine news :

1. Larger Skin Lesions More Likely to Be Melanoma
2. Most lethal melanomas are on scalp and neck
3. Survival rates appear lower for scalp and neck melanoma than for other sites
4. Larger skin lesions appear more likely to be melanomas
5. Melanomas on Scalp and Neck More Deadly
6. Gleevec Pushes Advanced Melanoma Into Remission
7. Interleukin-12 indicates survival prospects for melanoma patients
8. Drug Proves Effective in Slowing Melanomas
9. Indoor Tanning Association Launches Campaign Attacking Melanoma Hype
10. DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Companys Melanoma Advisory Board
11. Embryonic Stem Cell Protein Inhibits Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... for clear braces. People who want straight teeth without the extensive time commitment ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually invisible ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the ... popHealth Community in 2014. It is the culmination of collaborative efforts by ... Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first name ... the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to products ... as ANSI, ISO and proven test methods used in the field of Vision ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... -centric training, today announced the launch of a new research study, The Business ... skills needed to execute that strategy, and the actual success of achieving individual ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer Society , ... more than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, ... how to avoid this latter group, tune in to Lifestyle Magazine on ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... N.H. , March 27, 2017  iCAD ... analysis, workflow solutions and radiation therapy for the ... that PowerLook® Tomo Detection received Premarket Approval (PMA) ... PowerLook Tomo Detection is a first-of-its-kind, concurrent-read computer ... and is the latest innovation available on the ...
(Date:3/27/2017)... Calif. , March 27, 2017  Impax Laboratories, ... has appointed Paul M. Bisaro as Impax,s ... the Company,s Board, effective March 27, 2017. Mr. Bisaro ... served as Interim President and Chief Executive Officer since ... of generic and branded pharmaceutical experience, Mr. Bisaro, 56, ...
(Date:3/27/2017)... AUSTIN, Texas , March 27, 2017   Genprex, Inc. ... announced that Julien Pham , MD, the Company,s Chief Operating ... healthcare investor conferences. Sachs 5th Annual Cancer BioPartnering ... in New York, NY ... BioCentury 24th Annual Future Leaders ...
Breaking Medicine Technology: